Table 4.

Percentage of incidences of adverse events at months 1, 3 and 6 following treatment with erenumab in the overall population of patients treated with erenumab

	Month 1 (N = 162) N (%)	Month 3 (N = 100) N (%)	Month 6 (N = 73) N (%)
Constipation	32 (20%)	11 (11%)	4 (5%)
Cold-flu/like	25 (15%)	8 (8%)	2 (3%)
Generalised aches/pain	10 (6%)	1 (1%)	1 (1%)
Itchiness	8 (5%)	1 (1%)	1 (1%)
Injection site reaction (pain/skin redness)	5 (3%)	0 (0%)	1 (1%)
Muscle spasms	3 (2%)	0 (0%)	0 (0%)
Others	15 (9%)	4 (4%)	3 (4%)

N, number